• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管外科学会血管质量改进项目中,血管内动脉瘤修复术转换及原发性主动脉修复术治疗紧急和急诊指征后的结果。

Outcomes after endovascular aneurysm repair conversion and primary aortic repair for urgent and emergency indications in the Society for Vascular Surgery Vascular Quality Initiative.

作者信息

Scali Salvatore T, Runge Sara J, Feezor Robert J, Giles Kristina A, Fatima Javairiah, Berceli Scott A, Huber Thomas S, Beck Adam W

机构信息

Division of Vascular Surgery and Endovascular Therapy, University of Florida College of Medicine, Gainesville, Fla.

Division of Vascular Surgery and Endovascular Therapy, University of Florida College of Medicine, Gainesville, Fla.

出版信息

J Vasc Surg. 2016 Aug;64(2):338-347. doi: 10.1016/j.jvs.2016.02.028. Epub 2016 Jun 7.

DOI:10.1016/j.jvs.2016.02.028
PMID:27288102
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5545799/
Abstract

OBJECTIVE

Open conversion after endovascular aortic aneurysm repair (EVAR-c) is performed nonelectively in up to 60% of cases. EVAR-c has been reported to have significantly greater risk of postoperative morbidity and mortality than primary aortic repair, but few data exist on outcomes for symptomatic or ruptured presentations. This study determined outcomes and identified predictors of postoperative major adverse cardiac events (MACEs) and mortality for patients undergoing nonelective EVAR-c compared with nonelective primary aortic repair (PAR) in the Vascular Quality Initiative (VQI).

METHODS

All VQI patients undergoing urgent/emergency EVAR-c or urgent/emergency PAR from 2002 to 2014 were reviewed. Urgent presentation was defined by repair ≤24 hours of a nonelective admission, and emergency operations had clinical or radiographic evidence, or both, of rupture. End points included in-hospital MACE (myocardial infarction, dysrhythmia, congestive heart failure) and 30-day mortality. Possible covariates identified on univariate analysis (P < .2) were entered into a multivariable model, and stepwise elimination identified the best subset of predictors. Generalized estimating equations logistic regression analysis was used to determine the relative effect of EVAR-c compared with PAR on outcomes.

RESULTS

During the study interval, we identified 277 EVAR-c, and 118 (43%) underwent urgent/emergency repair. nonelective PAR was performed in 1388 of 6152 total (23%). EVAR-c patients were older (75 ± 9 vs 71 ± 10 years; P < .0001), more likely to be male (84% vs 74%; P = .02), and had a higher prevalence of hypertension (88% vs 79%; P = .02) and coronary artery disease (38% vs 27%; P = .01). No differences in MACE (EVAR-c, 31% [n = 34] vs PAR, 30% [n = 398]) or any major postoperative complication (EVAR-c, 57% [n = 63] vs PAR, 55% [n = 740]; P = .8) were found; however, 30-day mortality was significantly greater in EVAR-c (37% [n = 41]) than in (PAR, 24% [n = 291]; P = .003), with an odds ratio (OR) of 2.2 (95% confidence interval [CI], 1.04-4.77; P = .04) for EVAR-c. Predictors of any MACE included age (OR, × 1.03 for each additional year; 95% CI, 1.01-1.03; P = .0002), male gender (OR, 1.3; 95% CI, 1.03-1.67; P = .03), body mass index ≤20 kg/m (OR, 1.8; 95% CI, 1.13-2.87; P = .01), chronic obstructive pulmonary disease (OR, 1.2; 95% CI, 0.86-1.80; P = .25), congestive heart failure (OR, 1.5; 95% CI, 0.98-2.34; P = .06), preoperative chronic β-blocker use (OR, 1.3; 95% CI, 0.97-1.63; P = .09), and emergency presentation (OR, 2.3; 95% CI, 1.8-3.01; area under the curve, 0.70; P < .0001). Significant predictors for 30-day mortality were age (OR × 1.07 for each additional year; 95% CI, 1.05-1.09; P < .0001), female gender (OR, 1.6; 95% CI, 1.01-2.46; P = .04), preoperative creatinine >1.8 mg/dL (OR, 1.6; 95% CI, 1.04-2.35; P = .03), an emergency presentation (OR, 4.8; 95% CI, 2.93-7.93; P < .0001), and renal/visceral ischemia (OR, × 1.1 for each unit increase log (time-minutes); 95% CI, 1.02-1.22; area under the curve, 0.84; P = .01).

CONCLUSIONS

Nonelective EVAR-c patients are older and have higher prevalence of cardiovascular risk factors than PAR patients. Similar rates of postoperative complications occur; however, urgent/emergency EVAR-c has a significantly higher risk of 30-day mortality than nonelective PAR. Several variables are identified that predict outcomes after these repairs and may help risk stratify patients to further inform clinical decision making when patients present nonelectively with EVAR failure.

摘要

目的

在高达60%的病例中,血管腔内修复术后转为开放手术(EVAR-c)是非选择性进行的。据报道,与初次主动脉修复相比,EVAR-c术后发生并发症和死亡的风险显著更高,但关于有症状或破裂表现的患者的预后数据较少。本研究确定了在血管质量倡议(VQI)中接受非选择性EVAR-c与非选择性初次主动脉修复(PAR)的患者的术后主要不良心脏事件(MACE)和死亡率的预后情况,并确定了预测因素。

方法

回顾了2002年至2014年期间所有接受紧急/急诊EVAR-c或紧急/急诊PAR的VQI患者。紧急情况定义为在非选择性入院后≤24小时内进行修复,急诊手术有临床或影像学证据,或两者均有破裂证据。终点包括住院期间的MACE(心肌梗死、心律失常、充血性心力衰竭)和30天死亡率。单因素分析(P <.2)中确定的可能协变量被纳入多变量模型,并通过逐步消除确定最佳预测因子子集。使用广义估计方程逻辑回归分析来确定EVAR-c与PAR相比对预后的相对影响。

结果

在研究期间,我们确定了277例EVAR-c患者,其中118例(43%)接受了紧急/急诊修复。在6152例患者中,1388例(23%)进行了非选择性PAR。EVAR-c患者年龄更大(75±9岁 vs 71±10岁;P <.0001),男性比例更高(84% vs 74%;P =.02),高血压患病率更高(88% vs 79%;P =.02),冠状动脉疾病患病率更高(38% vs 27%;P =.01)。未发现MACE(EVAR-c组为31% [n = 34],PAR组为30% [n = 398])或任何主要术后并发症(EVAR-c组为57% [n = 63],PAR组为55% [n = 740];P =.8)存在差异;然而,EVAR-c组的30天死亡率显著高于PAR组(37% [n = 41] 对PAR组的24% [n = 291];P =.003),EVAR-c组的比值比(OR)为2.2(95%置信区间[CI],1.04 - 4.77;P =.04)。任何MACE的预测因素包括年龄(每增加一岁OR为×1.03;95% CI,1.01 - 1.03;P =.0002)、男性性别(OR,1.3;95% CI,1.03 - 1.67;P =.03)、体重指数≤20 kg/m(OR,1.8;95% CI,1.13 - 2.87;P =.01)、慢性阻塞性肺疾病(OR,1.2;95% CI,0.86 - 1.80;P =.25)、充血性心力衰竭(OR,1.5;95% CI,0.98 - 2.34;P =.06)、术前长期使用β受体阻滞剂(OR,1.3;95% CI,0.97 - 1.63;P =.09)和急诊情况(OR,2.3;95% CI,1.8 - 3.01;曲线下面积,0.70;P <.0001)。30天死亡率的显著预测因素为年龄(每增加一岁OR为×1.07;95% CI,1.05 - 1.09;P <.0001)、女性性别(OR,1.6;95% CI,1.01 - 2.46;P =.04)、术前肌酐>1.8 mg/dL(OR,1.6;95% CI,1.04 - 2.35;P =.03)、急诊情况(OR,4.8;95% CI,2.93 - 7.93;P <.0001)以及肾/内脏缺血(每单位增加log(时间 - 分钟)OR为×1.1;95% CI,1.02 - 1.22;曲线下面积,0.84;P =.01)。

结论

非选择性EVAR-c患者比PAR患者年龄更大,心血管危险因素患病率更高。术后并发症发生率相似;然而,紧急/急诊EVAR-c的30天死亡率显著高于非选择性PAR。确定了几个预测这些修复术后预后的变量,当患者非选择性出现EVAR失败时,这些变量可能有助于对患者进行风险分层,以进一步为临床决策提供信息。

相似文献

1
Outcomes after endovascular aneurysm repair conversion and primary aortic repair for urgent and emergency indications in the Society for Vascular Surgery Vascular Quality Initiative.血管外科学会血管质量改进项目中,血管内动脉瘤修复术转换及原发性主动脉修复术治疗紧急和急诊指征后的结果。
J Vasc Surg. 2016 Aug;64(2):338-347. doi: 10.1016/j.jvs.2016.02.028. Epub 2016 Jun 7.
2
Defining risk and identifying predictors of mortality for open conversion after endovascular aortic aneurysm repair.定义血管腔内主动脉瘤修复术后开放转换的风险并确定死亡预测因素。
J Vasc Surg. 2016 Apr;63(4):873-81.e1. doi: 10.1016/j.jvs.2015.09.058. Epub 2015 Nov 21.
3
Predictors of in-hospital adverse events after endovascular aortic aneurysm repair.血管内主动脉瘤修复术后住院期间不良事件的预测因素。
J Vasc Surg. 2019 Jul;70(1):80-91. doi: 10.1016/j.jvs.2018.10.093. Epub 2019 Feb 15.
4
Conversion from endovascular to open abdominal aortic aneurysm repair.从血管内修复转换为开放性腹主动脉瘤修复。
J Vasc Surg. 2016 Jul;64(1):76-82. doi: 10.1016/j.jvs.2015.12.055.
5
Contemporary outcomes of open complex abdominal aortic aneurysm repair.开放性复杂腹主动脉瘤修复术的当代疗效
J Vasc Surg. 2016 May;63(5):1195-200. doi: 10.1016/j.jvs.2015.12.038.
6
Outcomes for symptomatic abdominal aortic aneurysms in the American College of Surgeons National Surgical Quality Improvement Program.美国外科医师学会国家外科质量改进计划中症状性腹主动脉瘤的治疗结果。
J Vasc Surg. 2016 Aug;64(2):297-305. doi: 10.1016/j.jvs.2016.02.055. Epub 2016 Apr 14.
7
Validation of a preoperative prediction model for mortality within 1 year after endovascular aortic aneurysm repair of intact aneurysms.验证一种用于完整型腹主动脉瘤腔内修复术后 1 年内死亡率的术前预测模型。
J Vasc Surg. 2019 Aug;70(2):449-461.e3. doi: 10.1016/j.jvs.2018.10.122. Epub 2019 Mar 25.
8
Outcomes of endovascular abdominal aortic aneurysm repair in high-risk patients.高危患者血管腔内腹主动脉瘤修复术的疗效
J Vasc Surg. 2015 Apr;61(4):862-8. doi: 10.1016/j.jvs.2014.11.081. Epub 2015 Feb 19.
9
Outcomes after elective abdominal aortic aneurysm repair in obese versus nonobese patients.肥胖与非肥胖患者择期腹主动脉瘤修复术后的结果。
J Vasc Surg. 2018 Dec;68(6):1696-1705. doi: 10.1016/j.jvs.2018.03.414. Epub 2018 Jun 7.
10
Comparative predictors of mortality for endovascular and open repair of ruptured infrarenal abdominal aortic aneurysms.破裂性肾下腹主动脉瘤血管内修复与开放修复的死亡率比较预测因素。
Ann Vasc Surg. 2011 May;25(4):461-8. doi: 10.1016/j.avsg.2010.12.030.

引用本文的文献

1
Late post-EVAR abdominal aortic aneurysm rupture: a meta-analysis study.腔内修复术后晚期腹主动脉瘤破裂:一项荟萃分析研究
Arch Med Sci Atheroscler Dis. 2024 Jul 26;9:e152-e164. doi: 10.5114/amsad/190421. eCollection 2024.
2
Surgical Treatment of Sac Enlargement Due to Type II Endoleaks Following Endovascular Aneurysm Repair.血管内动脉瘤修复术后Ⅱ型内漏所致囊袋扩大的外科治疗
Ann Vasc Dis. 2023 Mar 25;16(1):1-7. doi: 10.3400/avd.ra.22-00115.
3
Risk factors for elective and urgent open conversion after EVAR-a retrospective observational study.血管内修复术(EVAR)后择期和紧急开放转换的风险因素:一项回顾性观察研究。
Vascular. 2024 Apr;32(2):243-253. doi: 10.1177/17085381221141118. Epub 2022 Nov 22.
4
Using the Idea, Development, Exploration, Assessment, Long-Term Study Framework for Devices (IDEAL-D) to Better Understand the Evolution of Evidence Surrounding Fenestrated Abdominal Aortic Endovascular Grafts.使用器械的理念、发展、探索、评估、长期研究框架(IDEAL-D)来更好地理解围绕开窗型腹主动脉腔内移植物的证据演变。
Ann Vasc Surg. 2019 Aug;59:293-299. doi: 10.1016/j.avsg.2019.02.010. Epub 2019 Apr 19.
5
Utility of the Vascular Quality Initiative in improving quality of care in Canadian patients undergoing vascular surgery.血管质量倡议在提高加拿大血管外科患者护理质量中的作用。
Can J Surg. 2019 Feb 1;62(1):66-69. doi: 10.1503/cjs.002218.
6
Increasing use of open conversion for late complications after endovascular aortic aneurysm repair.血管内主动脉瘤修复后晚期并发症行开放转化治疗的应用日益增多。
J Vasc Surg. 2019 Jun;69(6):1766-1775. doi: 10.1016/j.jvs.2018.09.049. Epub 2018 Dec 21.

本文引用的文献

1
Late Rupture of Abdominal Aortic Aneurysm After Previous Endovascular Repair: A Systematic Review and Meta-analysis.既往血管腔内修复术后腹主动脉瘤的晚期破裂:一项系统评价和荟萃分析
J Endovasc Ther. 2015 Oct;22(5):734-44. doi: 10.1177/1526602815601405. Epub 2015 Aug 18.
2
Outcomes of surgeon-modified fenestrated-branched endograft repair for acute aortic pathology.外科医生改良开窗分支型腔内修复术治疗急性主动脉病变的疗效
J Vasc Surg. 2015 Nov;62(5):1148-59.e2. doi: 10.1016/j.jvs.2015.06.133. Epub 2015 Aug 5.
3
Immediate and Late Open Conversion after Ovation Endograft.Ovation血管内移植物植入后的即刻和延迟开放转换
Ann Vasc Surg. 2015 Oct;29(7):1450.e5-9. doi: 10.1016/j.avsg.2015.04.062. Epub 2015 Jun 27.
4
Late open conversion after endovascular abdominal aortic aneurysm repair.血管腔内腹主动脉瘤修复术后的晚期开放转换
J Vasc Surg. 2015 May;61(5):1350-6. doi: 10.1016/j.jvs.2015.02.019. Epub 2015 Mar 26.
5
A comparison of open surgery versus endovascular repair of unstable ruptured abdominal aortic aneurysms.开放性手术与血管腔内修复术治疗不稳定破裂腹主动脉瘤的比较。
J Vasc Surg. 2014 Dec;60(6):1439-45. doi: 10.1016/j.jvs.2014.06.122. Epub 2014 Aug 4.
6
Elective endovascular aortic repair conversion for type Ia endoleak is not associated with increased morbidity or mortality compared with primary juxtarenal aneurysm repair.与初次肾下型腹主动脉瘤修复相比,择期血管内主动脉修复转换治疗 Ia 型内漏并不增加发病率或死亡率。
J Vasc Surg. 2014 Aug;60(2):286-294.e1. doi: 10.1016/j.jvs.2014.02.046. Epub 2014 Mar 27.
7
Late graft explants in endovascular aneurysm repair.血管内动脉瘤修复术中的晚期移植物外植体
J Vasc Surg. 2014 Apr;59(4):886-93. doi: 10.1016/j.jvs.2013.10.079. Epub 2013 Dec 28.
8
Comparative effectiveness of endovascular versus open repair of ruptured abdominal aortic aneurysm in the Medicare population.在 Medicare 人群中,血管内与开放修复破裂腹主动脉瘤的比较效果。
J Vasc Surg. 2014 Mar;59(3):575-82. doi: 10.1016/j.jvs.2013.08.093. Epub 2013 Dec 15.
9
Late open conversion after failed endovascular aortic aneurysm repair.血管内主动脉瘤修复失败后的晚期开放转换。
J Vasc Surg. 2014 Feb;59(2):291-7. doi: 10.1016/j.jvs.2013.07.106. Epub 2013 Oct 16.
10
Endovascular aortic aneurysm repair in patients with hostile neck anatomy.血管内主动脉瘤修复术治疗具有挑战性颈部解剖结构的患者。
J Endovasc Ther. 2013 Oct;20(5):623-37. doi: 10.1583/13-4320MR.1.